USPTO Examiner EDWARDS JESSICA FAYE - Art Unit 1657

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19021675LACTICASEIBACILLUS RHAMNOSUS AFY01 AND APPLICATION OF PRODUCT PREPARED FROM LACTICASEIBACILLUS RHAMNOSUS AFY01 IN INFLAMMATORY COLON CANCERJanuary 2025July 2025Allow610NoNo
18972671PROBIOTICS COMPOSITIONS AND METHOD OF USING THE SAME TO ENHANCE GROWTH AND SOCIAL FUNCTION IN CHILDRENDecember 2024March 2026Allow1521NoNo
18541328COMPOSITION FOR TREATING OF FACIAL DYSMORPHISM IN MUCOPOLYSACCHARIDOSISDecember 2023December 2025Abandon2410NoNo
18559060EXIGUOBACTERIUM INDICUM AND APPLICATION THEREOF IN SYNTHESIS OF NANO-SELENIUMNovember 2023December 2024Allow1410NoNo
18485543Construction Method and Application of Microorganism Capable of Realizing High Production of Lacto-N-neotetraoseOctober 2023July 2024Allow911YesNo
18447649O-METHYLTRANSFERASE PROTEIN WITH HIGHLY SPECIFIC CATALYTIC FUNCTION FOR MULTIPLE BIAS PARENT NUCLEI AND ENCODING GENE AND USE THEREOFAugust 2023June 2024Allow1011YesNo
18267969PROBIOTICS COMPOSITIONS AND METHOD OF USING THE SAME TO ENHANCE GROWTH AND SOCIAL FUNCTION IN CHILDRENJune 2023March 2026Allow3321NoNo
18191201METHOD FOR PREPARING FIBER MATERIAL FROM BANANA PSEUDOSTEMMarch 2023April 2025Abandon2530NoNo
18098504METHOD FOR PREVENTING AND/OR TREATING HELICOBACTER PYLORI-RELATED DISEASE BY USING PARABACTEROIDES GOLDSTEINII AND ITS METABOLITESJanuary 2023September 2025Abandon3210NoNo
18095357COMPOSITIONS AND METHODS FOR ACYLATED CONSUMABLESJanuary 2023May 2024Abandon1611NoNo
18148019COMPOSITION FOR TREATING OF FACIAL DYSMORPHISM IN MUCOPOLYSACCHARIDOSISDecember 2022March 2024Abandon1510NoNo
18145911SEPARATION METHOD AND ENRICHMENT CULTURE METHOD OF PSEUDOMONAS, AND REMEDIATION METHOD FOR CONTAMINATED SOILDecember 2022November 2025Allow3520YesNo
18085674POLYMERASES, COMPOSITIONS, AND METHODS OF USEDecember 2022September 2025Abandon3301NoNo
18002675METHODS FOR PREPARING PANTOIC ACID, PANTOTHENIC ACID AND PANTHENOL AS WELL AS SALTS THEREOFDecember 2022July 2025Allow3110NoNo
18071215METHOD FOR ENHANCING SPORTS PERFORMANCE AND ALLEVIATING SARCOPENIA WITH STREPTOCOCCUS THERMOPHILES ST7 FERMENTATION PRODUCT COMPOSITIONNovember 2022January 2025Abandon2520NoNo
18054546Method for Isolating and Purifying Bacteriocin Against Drug-Resistant Staphylococcus aureusNovember 2022March 2024Allow1720YesNo
17916368COMPOSITIONS AND METHODS FOR INHIBITING VIBRIO INFECTIONSeptember 2022November 2025Abandon3801NoNo
17955546METHODS FOR PRODUCING EGGSHELL MEMBRANE HYDROLYSATESSeptember 2022July 2024Abandon2121NoNo
17954325Composition And Method for Modulating Hydrogen Ion Physiology Related to Weight Loss and MetabolismSeptember 2022April 2024Abandon1920NoNo
17914703COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, ENHANCING DRUG POTENCY AND TREATING VIRAL INFECTIONS, AND METHODS FOR MAKING AND USING SAMESeptember 2022November 2025Abandon3811NoNo
17951848HETEROLOGOUS EXPRESSION OF PHOSPHITE DEHYDROGENASE IN PICOCHLORUM SPP.September 2022September 2024Allow2320NoNo
17930462Screening of Engineered Biocatalysts for Oxyfunctionalization of OlefinsSeptember 2022February 2025Abandon2931YesNo
17904203VIABLE BACTERIAL HOST CELLAugust 2022August 2024Abandon2411NoNo
17791752METHODS OF PRODUCING LACTIC ACID FROM UNMODIFIED STARCHJuly 2022July 2025Abandon3601NoNo
17852841INTEGRATED CONVERSION AND OLIGOMERIZATION OF BIO-DERIVED ALCOHOLSJune 2022March 2026Abandon4441YesNo
17784439METHOD FOR CONTINUOUS PROTEIN RECOVERINGJune 2022August 2025Abandon3801NoNo
17772464RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOFApril 2022August 2025Abandon3911NoNo
17772222FRUCTOSE-6-PHOSPHATE 3-EPIMERASE AND USE THEREOFApril 2022December 2025Abandon4421NoNo
17754062STRAIN FOR PRODUCING LIPASE AND APPLICATION THEREOFMarch 2022September 2024Allow3010NoNo
17753739ALLULOSE 3-EPIMERASE MUTANT, ENGINEERED BACTERIUM EXPRESSING SAME, AND IMMOBILIZED ENZYME AND IMMOBILIZATION METHOD THEREOFMarch 2022February 2026Allow4721YesNo
17690446BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORSMarch 2022February 2025Abandon3601NoNo
17640246Improved Alpha-Galactosidase Protein for Enzyme Replacement Therapy (ERT) and Methods of UseMarch 2022October 2025Allow4421NoNo
17618665Glycosyltransferase Mutant and Use ThereforDecember 2021July 2025Abandon4321NoNo
17618091Enzymatic Reaction Composition, Method for Increasing Amount of Adenosine Triphosphate (ATP) in Enzymatic Reaction and Application ThereofDecember 2021November 2024Abandon3501NoNo
17610278METHODS AND CELLS FOR MICROBIAL PRODUCTION OF PHYTOCANNABINOIDS AND PHYTOCANNABINOID PRECURSORSNovember 2021June 2025Allow4321NoNo
17508444METHOD FOR MICROSCOPIC EXAMINATION OF PHYTOPLANKTONOctober 2021November 2024Abandon3710NoNo
17601027POLYPEPTIDES HAVING BETA-GLUCANASE ACTIVITY, POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF IN CLEANING AND DETERGENT COMPOSITIONSOctober 2021July 2025Abandon4611NoNo
17440172NOVEL OF L-THREONINE DEHYDRATASE VARIANT AND METHOD OF PRODUCING L-ISOLEUCINE USING THE SAMESeptember 2021August 2025Allow4721YesNo
17438810MICROBIAL PRODUCTION OF COMPOUNDSSeptember 2021September 2024Abandon3701NoNo
17399423Mutant of Nitrile Hydratase Derived from Caldalkalibacillus thermarumAugust 2021July 2024Allow3611YesNo
17429560CHEMICALLY MODIFIED LIGNIN AS REDUCING AGENT FOR ENZYMATIC HYDROLYSIS OF LIGNOCELLULOSIC BIOMASSAugust 2021April 2025Abandon4420NoNo
17423615PSEUDOMONAS GRAMINIS STRAIN CAPABLE OF DEGRADING CELLULOSE AT LOW TEMPERATURE AND USE THEREOFJuly 2021February 2025Abandon4320NoNo
17340466Method for Producing Maltodextrin with Single Polymerization Degree by Multienzyme CouplingJune 2021November 2024Allow4120NoNo
17323769PRODUCTION OF HUMAN MILK OLIGOSACCHARIDES IN MICROBIAL HOSTS WITH ENGINEERED IMPORT / EXPORTMay 2021May 2025Allow4832YesNo
17288435TARGETED CHONDROITINASE ABC FUSION PROTEINS AND COMPLEXES THEREOFApril 2021February 2026Allow5841YesNo
17284944METHOD FOR COLLECTING MICROORGANISM CELLApril 2021April 2025Abandon4821NoNo
17278410PESTICIDAL COMBINATIONS OF YERSINIA AND BACILLUSMarch 2021May 2025Abandon5041NoNo
17271615NEW PURIFICATION METHODFebruary 2021May 2024Abandon3910NoNo
17164025Methods And Compositions For Producing Fatty AlcoholsFebruary 2021July 2024Abandon4111YesNo
17261365METHODS OF SEPARATING HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC PROCESSESJanuary 2021March 2025Abandon5021NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner EDWARDS, JESSICA FAYE - Prosecution Strategy Guide

Executive Summary

Examiner EDWARDS, JESSICA FAYE works in Art Unit 1657 and has examined 18 patent applications in our dataset. With an allowance rate of 33.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner EDWARDS, JESSICA FAYE's allowance rate of 33.3% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by EDWARDS, JESSICA FAYE receive 1.78 office actions before reaching final disposition. This places the examiner in the 39% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by EDWARDS, JESSICA FAYE is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +64.6% benefit to allowance rate for applications examined by EDWARDS, JESSICA FAYE. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.0% of applications are subsequently allowed. This success rate is in the 38% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.